AMYT.L ( MKap 50 M€) potentieller Blockbuster mit P3 Daten im 2H19 (Seite 2)
eröffnet am 02.02.19 20:48:07 von
neuester Beitrag 09.01.23 09:01:04 von
neuester Beitrag 09.01.23 09:01:04 von
Beiträge: 88
ID: 1.297.401
ID: 1.297.401
Aufrufe heute: 0
Gesamt: 10.887
Gesamt: 10.887
Aktive User: 0
ISIN: GB00BKLTQ412 · WKN: A2PQ6T
1,9400
EUR
0,00 %
0,0000 EUR
Letzter Kurs 11.01.22 Lang & Schwarz
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0000 | +99.900,00 | |
| 6,0000 | +16,73 | |
| 0,8750 | +16,67 | |
| 12,180 | +11,64 | |
| 109,19 | +10,80 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,2400 | -10,00 | |
| 36,51 | -10,95 | |
| 5,4300 | -10,98 | |
| 14,720 | -12,12 | |
| 1,2000 | -14,29 |
Beitrag zu dieser Diskussion schreiben
FeedbackHöchster Tagesschluss
seit 5 Jahren....Nasdaq Registrierung eingereicht.....Daten in 3 Monaten....
wait and see 😎
wenn es heute grün schließt = 20. Tag in Folge Grün.....
noch 4 Pence zum 5 Jahreshoch.....
noch 4 Pence zum 5 Jahreshoch.....
Kleiner Insider Kauf...
https://www.investegate.co.uk/amryt-pharma-plc--amyt-/rns/di…
und nur noch 5 % bis zum höchsten Schlußkurs der letzten 5 Jahre....danach Ausbruch auf 4 € ?
https://www.investegate.co.uk/amryt-pharma-plc--amyt-/rns/di…
und nur noch 5 % bis zum höchsten Schlußkurs der letzten 5 Jahre....danach Ausbruch auf 4 € ?
Erweiterung
Vertrieb von Myalepta....https://www.proactiveinvestors.co.uk/companies/news/921016/a…gleichzeitig erreichen des 2 Jahreshochs...
Zahlen Q1
https://finance.yahoo.com/news/amryt-pharma-plc-q1-2020-1100…Sehr gute Q1 Ergebnisse, trotz Phase III für AP101 - positiver Cashflow
nun muss nur noch die PIII erfolgreich sein....abwarten bis Anfang Oktober
Trading Spotlight
Filsuvez Markenname für AP101
Rekrutierung abgeschlossen und Daten für Ende Q3 / Anfang Q4 angesagt.Des Weiteren wird über ein Nasdaq Listing nachgedacht....
https://finance.yahoo.com/news/filsuvez-confirmed-global-bra…
Mal schauen was 2020 so alles bringt...
vielleicht ist ja die Tage schon was Neues dabeihttps://www.proactiveinvestors.co.uk/companies/news/910685/a…
Amryt Pharma Reinstated Buy at Stifel; PT 430 pence
Amryt Pharma Says Nine-Month Pro Forma Revenue Rose 20%
By Adria Calatayud
Amryt Pharma PLC (AMYT.LN) said Tuesday that pro forma revenue for the first nine months of 2019 rose 20% following the completion of its acquisition of Aegerion Pharmaceuticals Inc. in September.
The Dublin-based, London-listed biopharmaceutical company said the combined group had revenue of $113.1 million for the nine months to Sept. 30 compared with $94.5 million in the year-earlier period.
After the completion of the acquisition, Amryt now has two commercial-stage assets and infrastructure in place through which it is commercializing them in North America, Europe, Middle East, Africa and Latin America.
Amryt Pharma Is Looking Healthy: Shore Capital -- Market Talk
0932 GMT - Amryt Pharma's 9-months results demonstrate momentum in the underlying businesses in spite of the bankruptcy process of its recently-acquired Aegerion business, says Shore Capital. The London-listed biopharmaceutical company said that revenue in the period rose 20%. "Importantly cash of $61.2 million at 31 October 2019 should be more than enough to see Amryt through to the Phase 3 data for the lead asset AP101, with the trial due to be fully enrolled 'in coming months' and top-line data anticipated in late 1H 2020," Shore Capital says.
Amryt Pharma Says Nine-Month Pro Forma Revenue Rose 20%
By Adria Calatayud
Amryt Pharma PLC (AMYT.LN) said Tuesday that pro forma revenue for the first nine months of 2019 rose 20% following the completion of its acquisition of Aegerion Pharmaceuticals Inc. in September.
The Dublin-based, London-listed biopharmaceutical company said the combined group had revenue of $113.1 million for the nine months to Sept. 30 compared with $94.5 million in the year-earlier period.
After the completion of the acquisition, Amryt now has two commercial-stage assets and infrastructure in place through which it is commercializing them in North America, Europe, Middle East, Africa and Latin America.
Amryt Pharma Is Looking Healthy: Shore Capital -- Market Talk
0932 GMT - Amryt Pharma's 9-months results demonstrate momentum in the underlying businesses in spite of the bankruptcy process of its recently-acquired Aegerion business, says Shore Capital. The London-listed biopharmaceutical company said that revenue in the period rose 20%. "Importantly cash of $61.2 million at 31 October 2019 should be more than enough to see Amryt through to the Phase 3 data for the lead asset AP101, with the trial due to be fully enrolled 'in coming months' and top-line data anticipated in late 1H 2020," Shore Capital says.
die sind auch mehr im "Trading Stop" als handelbar..
Amryt Pharma Shares Temporarily Suspended On Aegerion Buy
in Amryt Pharma PLC were suspended on Tuesday over its acquisition of Aegerion Pharmaceuticals Inc, which is considered a reverse takeover under...
Amryt Pharma Shares Temporarily Suspended On Aegerion Buy
in Amryt Pharma PLC were suspended on Tuesday over its acquisition of Aegerion Pharmaceuticals Inc, which is considered a reverse takeover under...
Durchsuchen
